HighMorph: De Novo Cyclic Peptide Sequence Design via Protein–Protein Interaction Recapitulation
Cyclic peptides have emerged as a compelling class of bioactive scaffolds, but de novo design of target-binding cyclic peptides from protein structures remains challenging. Here, we present HighMorph, an interaction-guided framework that combines protein–protein interaction information with artificial intelligence for rational cyclic peptide design. HighMorph integrates Monte Carlo tree search with a Transformer-based policy-value network to efficiently explore cyclic peptide sequence space, while incorporating explicit atomic-level hydrogen bond constraints extracted from reference protein–protein complexes to guide sequence optimization. The framework is systematically validated on two clinically relevant targets, programmed death-ligand 1 (PD-L1) and kallikrein-related peptidase 4 (KLK4). Notably, 33.3% and 40% of the generated candidates are active against PD-L1 and KLK4, respectively, with active cyclic peptides exhibiting micromolar binding affinities (approximately 10–6 M). These results validate our approach for cyclic peptide design. Additionally, interaction analysis provides insights for developing therapeutics targeting challenging protein interfaces.